跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
multi-specific antibodies
首页
药物
multi-specific antibodies
multi-specific antibodies
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTI-SPECIFIC BINDING MOLECULES
EP 4182025 A1
申请人: NOVARTIS AG
优先权: 2020
EP
US
WO
7 件公开
MULTI-SPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF
EP 3645050 A4
申请人: SYSTIMMUNE INC
优先权: 2017
CN
EP
US
WO
6 件公开
EP 3645048 A4
申请人: SYSTIMMUNE INC
优先权: 2017
CN
EP
US
WO
4 件公开
US 11787863 B2
申请人: SYSTIMMUNE INC
优先权: 2017
US
MULTI-SPECIFIC ANTIBODY CONSTRUCTS
EP 3807318 A4
申请人: BIOATLA INC
优先权: 2018
CN
EP
US
WO
6 件公开
MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX
EP 3256164 B1
申请人: MEMORIAL SLOAN KETTERING CANCER CENTER
优先权: 2015
EP
US
WO
6 件公开
CD38 AND ICAM1 ANTIBODIES AND USES THEREOF
EP 3883967 A4
申请人: VIRTUOSO BINCO INC
优先权: 2018
CN
EP
US
WO
5 件公开
EFFLUX PUMP-CANCER ANTIGEN MULTI-SPECIFIC ANTIBODIES AND COMPOSITIONS, REAGENTS, KITS AND METHODS RELATED THERETO
EP 3946626 A1
申请人: KENJOCKETY BIOTECHNOLOGY INC
优先权: 2019
CN
EP
US
WO
5 件公开
MULTI-SPECIFIC ANTIBODIES IN USES THEREOF IN AVIDITY RECEPTOR CROSSLINKING AND IMMUNE MODULATION
EP 4466020 A4
申请人: LYVGEN BIOPHARMA HOLDINGS LTD
优先权: 2022
EP
US
WO
5 件公开
MULTI-SPECIFIC PROTEIN MOLECULES AND USES THEREOF
EP 3906055 A2
申请人: TRIO PHARMACEUTICALS INC
优先权: 2019
CN
EP
US
WO
4 件公开
MONOSPECIFIC AND MULTI-SPECIFIC ANTIBODIES
EP 4034549 A4
申请人: BEIJING STARMAB BIOMED TECH LTD
优先权: 2019
CN
EP
US
WO
4 件公开
EP 4547270 A4
申请人: BEIJING STARMAB BIOMED TECH LTD
优先权: 2022
EP
US
WO
3 件公开
EP 4805036 A1
申请人: BEIJING STARMAB BIOMED TECH LTD
优先权: 2023
CN
EP
WO
3 件公开
ANTI-SERUM ALBUMIN ANTIBODIES
EP 4073114 A4
申请人: CULLINAN ONCOLOGY INC
优先权: 2019
CN
EP
US
WO
4 件公开
第 1 / 10 页
上一页
下一页
药物
反馈